| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6092074 | Gastroenterology | 2016 | 33 Pages |
Abstract
In a large prospective observational cohort study, a 12-week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811.
Keywords
SVRFDANS3/4A protease inhibitorAASLDSVR12NS5BIDSAAmerican Association for the Study of Liver DiseaseInfectious Diseases Society of AmericaFood and Drug Administrationadverse eventconfidence intervalModel for End-Stage Liver DiseaseHepatitis C virusHCVChronic hepatitisSustained virologic responseMELD
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jama M. Darling, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Thomas G. Stewart, Michael W. Fried, David R. Nelson,